A Study to Evaluate the Safety of 2-OHOA Added to Standard of Care in Newly-diagnosed Glioblastoma Patients
Status:
Completed
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and tolerability of 2-OHOA added to
first-line treatment for subjects with newly diagnosed glioblastoma (GBM), and to determine
the highest safe dose of 2-OHOA administered orally when added to the concurrent phase of
treatment with temozolomide (TMZ) and radiation therapy (RT) or when added to the maintenance
phase of treatment with TMZ (once TMZ 200 g/m2/day is started).